Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, et al.
Cell Metabolism (2016) Vol. 24, Iss. 1, pp. 51-62
Open Access | Times Cited: 216

Showing 26-50 of 216 citing articles:

Obesity-induced inflammation: connecting the periphery to the brain
Ophélia Le Thuc, Cristina García‐Cáceres
Nature Metabolism (2024) Vol. 6, Iss. 7, pp. 1237-1252
Closed Access | Times Cited: 19
GLP-1/glucagon receptor co-agonism for treatment of obesity
Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, et al.
Diabetologia (2017) Vol. 60, Iss. 10, pp. 1851-1861
Open Access | Times Cited: 144
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 719-738
Open Access | Times Cited: 127
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Christoffer Clemmensen, Brian Finan, Timo D. Müller, et al.
Nature Reviews Endocrinology (2018) Vol. 15, Iss. 2, pp. 90-104
Closed Access | Times Cited: 104
Gut hormone polyagonists for the treatment of type 2 diabetes
Sara J. Brandt, A. Götz, Matthias H. Tschöp, et al.
Peptides (2018) Vol. 100, pp. 190-201
Open Access | Times Cited: 100
Hypothalamic AMPK and energy balance
Miguel López
European Journal of Clinical Investigation (2018) Vol. 48, Iss. 9
Open Access | Times Cited: 98
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, et al.
Molecular Metabolism (2017) Vol. 6, Iss. 5, pp. 440-446
Open Access | Times Cited: 96
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Andreas Evers, Torsten Haack, M. Lorenz, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 10, pp. 4293-4303
Closed Access | Times Cited: 94
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Alexei Kharitonenkov, Richard D. DiMarchi
Journal of Internal Medicine (2016) Vol. 281, Iss. 3, pp. 233-246
Open Access | Times Cited: 93
Central administration of GLP-1 and GIP decreases feeding in mice
Cherl NamKoong, Min Sun Kim, Byeong-Tak Jang, et al.
Biochemical and Biophysical Research Communications (2017) Vol. 490, Iss. 2, pp. 247-252
Open Access | Times Cited: 91
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
Valentina Pirro, Kenneth D. Roth, Yanzhu Lin, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 2, pp. 363-378
Open Access | Times Cited: 83
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 81
Gut-brain communication and obesity: understanding functions of the vagus nerve
Hans‐Rudolf Berthoud, Vance L. Albaugh, Winfried Neuhuber
Journal of Clinical Investigation (2021) Vol. 131, Iss. 10
Open Access | Times Cited: 66
Small extracellular vesicle-mediated targeting of hypothalamic AMPKα1 corrects obesity through BAT activation
Edward Milbank, Nathalia Romanelli Vicente Dragano, Ismael González‐García, et al.
Nature Metabolism (2021) Vol. 3, Iss. 10, pp. 1415-1431
Closed Access | Times Cited: 65
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Shu-Chen Lu, Michelle Chen, Larissa Atangan, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 5, pp. 100263-100263
Open Access | Times Cited: 63
Multifaceted actions of melanin-concentrating hormone on mammalian energy homeostasis
Omar Al–Massadi, Carlos Diéguez, Marc Schneeberger, et al.
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 12, pp. 745-755
Closed Access | Times Cited: 60
Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
David S. Mathiesen, Asger Lund, Tina Vilsbøll, et al.
Frontiers in Endocrinology (2021) Vol. 11
Open Access | Times Cited: 56
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Ricardo J. Samms, Guo‐Fang Zhang, Wentao He, et al.
Molecular Metabolism (2022) Vol. 64, pp. 101550-101550
Open Access | Times Cited: 48
The molecular pharmacology of glucagon agonists in diabetes and obesity
Aaron Novikoff, Timo D. Müller
Peptides (2023) Vol. 165, pp. 171003-171003
Open Access | Times Cited: 40
Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes
André Scheen
Annales d Endocrinologie (2023) Vol. 84, Iss. 2, pp. 316-321
Closed Access | Times Cited: 33
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 27
The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
Thomas Leth Jensen, Andreas Brønden, Kristian Karstoft, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 373-382
Open Access | Times Cited: 11
NK2R control of energy expenditure and feeding to treat metabolic diseases
Frederike Sass, Tao Ma, Jeppe H. Ekberg, et al.
Nature (2024) Vol. 635, Iss. 8040, pp. 987-1000
Open Access | Times Cited: 10
Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102343-102343
Closed Access | Times Cited: 8
Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
Gary D. Miller
American Journal of Lifestyle Medicine (2017) Vol. 13, Iss. 6, pp. 586-601
Open Access | Times Cited: 82

Scroll to top